Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
British Journal of Clinical Pharmacology|February 19, 2002
The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activityDonna J Belle, John T Callaghan, J Christopher Gorski, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 30, 2025
Pharmacogenetics of steady-state metabolism, pharmacokinetics, and adverse effects of voriconazole in healthy participantsYanting Phoebe Wu, Ayşe Gelal, Chisook Moon, et al.
Antimicrobial Agents and Chemotherapy|September 8, 2016
Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy VolunteersZeruesenay Desta, Ingrid F Metzger, Nancy Thong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2003
A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignanciesBahram Forouzesh, Chris H Takimoto, Andrew Goetz, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 3, 2018
Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics SubcommitteeJason L Vassy, Annjanette Stone, John T Callaghan, et al.
Clinical Pharmacology and Therapeutics|January 10, 2025
Return of Clinically Actionable Pharmacogenetic Results From Molecular Tumor Board DNA Sequencing Data: Workflow and Estimated CostsHyunwoo Koo, Tayler B Smith, John T Callaghan, et al.
Current Therapeutic Research, Clinical and Experimental|October 30, 2014
Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteersIngrid F Metzger, Troy C Quigg, Noam Epstein, et al.
Frontiers in Cardiovascular Medicine|January 2, 2023
Association of QT interval-prolonging drugs with clinical trial eligibility in patients with advanced cancerElizabeth J Rowe, Tyler Shugg, Reynold C Ly, et al.
JCO Precision Oncology|February 24, 2022
Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid CancersTyler Shugg, Reynold C Ly, Elizabeth J Rowe, et al.
Pharmacogenomics|February 21, 2019
Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trialCathy R Fulton, Yong Zang, Zeruesenay Desta, et al.
Pageof 2